On August 5, Encompass Health (NYSE:EHC) reported second quarter results that beat its own expectations by enough to raise full year guidance twice in the same release, first on revenue and then on profit. Net operating revenue climbed 9.6% to $1.597 billion, and adjusted earnings per share rose 10.7% to $1.55. For the largest owner of inpatient rehabilitation hospitals in the country, that combination of faster patient volume and wider guidance is the kind of quarter that makes a scaling story look sustainable rather than seasonal.
More Patients, More Beds, More Cash
The volume numbers back up the growth story. Encompass Health discharged 68,895 patients in the quarter, up 5.6% from a year earlier, and same-store discharges still grew 2.8% even as the network keeps adding capacity. Net patient revenue per discharge rose 3.9% to $22,521, so the company is being paid more for each patient on top of treating more of them. That capacity keeps expanding: the company opened three hospitals totaling 139 beds and added 54 beds to existing facilities in the first half of the year, with five more hospitals and over 100 additional beds planned before year-end.
Management raised full-year guidance across the board, lifting expected revenue to a range of $6.41 billion to $6.49 billion, adjusted EBITDA to $1.365 billion to $1.395 billion, and adjusted earnings per share to $6.02 to $6.25, each range higher than what the company projected just a quarter earlier. The board also increased the common stock repurchase authorization to $1 billion on July 23, after the company had already bought back $145.8 million of stock so far this year. That buying has shrunk diluted shares outstanding to 100.0 million from 102.3 million a year ago, so each share now claims a bigger piece of a growing business.
The Bill For Growth Is Rising
Not every line moved in the same direction. Adjusted free cash flow actually fell 4.8% to $177.0 million even as adjusted EBITDA grew, because maintenance capital spending jumped to $66.2 million in the quarter from $45.1 million a year earlier. All that hospital and bed expansion has to be financed, and the balance sheet shows it: long-term debt climbed to $2.598 billion from $2.447 billion at the end of 2025, after the company issued $500 million in new bonds during the first half of the year. Interest expense rose to $32.8 million from $30.4 million, and the quarter also included a $3.2 million loss on early extinguishment of debt.
The stock buyback that boosted earnings per share was also running low before it got topped up: the company had roughly $188 million left under its prior authorization as of June 30, before the board raised the ceiling to $1 billion. That timing suggests repurchases were close to tapping out right when the company needed the program to keep supporting its per-share numbers.
What The Smart Money Sees
Hedge fund ownership of Encompass Health rose to 49 funds from 44 in the prior quarter, which points to institutions adding rather than trimming the position. Short interest sits at just 3.74% of the float, a level that suggests little organized skepticism toward the stock. The shares trade at a forward price-to-earnings ratio of 18.98 as of September 4, a multiple that already prices in a fair amount of the growth the company just delivered. That combination suggests that the market has largely caught up to the story rather than doubting it.
Where This Leaves Investors
Encompass Health’s second quarter gives both sides real evidence. Patient volume is climbing, guidance keeps rising, and the buyback keeps shrinking the share count, the marks of a business scaling on its own terms. But that growth is being financed with more debt and heavier capital spending, and free cash flow slipped even as profit grew. The next few quarters will show whether new hospitals and beds convert into revenue fast enough to outrun the debt used to build them, or whether a thinner cash flow cushion becomes the story instead.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
